GB2044263A - Reduction of halogenated ethers - Google Patents
Reduction of halogenated ethers Download PDFInfo
- Publication number
- GB2044263A GB2044263A GB8006975A GB8006975A GB2044263A GB 2044263 A GB2044263 A GB 2044263A GB 8006975 A GB8006975 A GB 8006975A GB 8006975 A GB8006975 A GB 8006975A GB 2044263 A GB2044263 A GB 2044263A
- Authority
- GB
- United Kingdom
- Prior art keywords
- ether
- product
- reaction
- aliphatic ether
- reactant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000002170 ethers Chemical class 0.000 title description 21
- 230000009467 reduction Effects 0.000 title description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 claims abstract description 65
- 238000000034 method Methods 0.000 claims abstract description 35
- 230000008569 process Effects 0.000 claims abstract description 33
- -1 methyl-methyl Chemical group 0.000 claims abstract description 19
- 125000001931 aliphatic group Chemical group 0.000 claims abstract description 13
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 12
- 239000001257 hydrogen Substances 0.000 claims abstract description 12
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 125000005843 halogen group Chemical group 0.000 claims abstract description 4
- 150000007529 inorganic bases Chemical class 0.000 claims abstract description 3
- 238000006243 chemical reaction Methods 0.000 claims description 47
- 239000000376 reactant Substances 0.000 claims description 17
- 239000000203 mixture Substances 0.000 claims description 16
- 239000003054 catalyst Substances 0.000 claims description 14
- 229910052751 metal Inorganic materials 0.000 claims description 11
- 239000002184 metal Substances 0.000 claims description 11
- 150000003839 salts Chemical class 0.000 claims description 5
- 150000001412 amines Chemical class 0.000 claims description 3
- 239000000843 powder Substances 0.000 claims description 3
- COLOHWPRNRVWPI-UHFFFAOYSA-N 1,1,1-trifluoroethane Chemical compound [CH2]C(F)(F)F COLOHWPRNRVWPI-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- VUWZPRWSIVNGKG-UHFFFAOYSA-N fluoromethane Chemical compound F[CH2] VUWZPRWSIVNGKG-UHFFFAOYSA-N 0.000 claims description 2
- 230000003444 anaesthetic effect Effects 0.000 abstract description 18
- 238000004519 manufacturing process Methods 0.000 abstract description 9
- 229940124326 anaesthetic agent Drugs 0.000 abstract description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 47
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 42
- 239000000047 product Substances 0.000 description 36
- JPGQOUSTVILISH-UHFFFAOYSA-N enflurane Chemical compound FC(F)OC(F)(F)C(F)Cl JPGQOUSTVILISH-UHFFFAOYSA-N 0.000 description 22
- 229960000305 enflurane Drugs 0.000 description 22
- 239000006227 byproduct Substances 0.000 description 18
- 239000000463 material Substances 0.000 description 15
- 238000006722 reduction reaction Methods 0.000 description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 12
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 10
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 9
- 239000011541 reaction mixture Substances 0.000 description 9
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 150000001875 compounds Chemical class 0.000 description 8
- 238000002360 preparation method Methods 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000000460 chlorine Substances 0.000 description 7
- 235000017168 chlorine Nutrition 0.000 description 7
- 235000019441 ethanol Nutrition 0.000 description 7
- 150000002367 halogens Chemical class 0.000 description 7
- 229960002725 isoflurane Drugs 0.000 description 7
- 229910052801 chlorine Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 5
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 5
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 5
- 229910052799 carbon Inorganic materials 0.000 description 5
- 229910052802 copper Inorganic materials 0.000 description 5
- 239000010949 copper Substances 0.000 description 5
- 238000004817 gas chromatography Methods 0.000 description 5
- 229910052736 halogen Inorganic materials 0.000 description 5
- 150000001335 aliphatic alkanes Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 150000002739 metals Chemical class 0.000 description 4
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N N,N-Diethylethanamine Substances CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 3
- 229910052794 bromium Inorganic materials 0.000 description 3
- 125000001246 bromo group Chemical group Br* 0.000 description 3
- 125000001309 chloro group Chemical group Cl* 0.000 description 3
- 239000013527 degreasing agent Substances 0.000 description 3
- 238000005237 degreasing agent Methods 0.000 description 3
- 238000006704 dehydrohalogenation reaction Methods 0.000 description 3
- 238000006073 displacement reaction Methods 0.000 description 3
- 230000007062 hydrolysis Effects 0.000 description 3
- 238000006460 hydrolysis reaction Methods 0.000 description 3
- 230000000269 nucleophilic effect Effects 0.000 description 3
- 238000010992 reflux Methods 0.000 description 3
- 229920006384 Airco Polymers 0.000 description 2
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 238000005705 Cannizzaro reaction Methods 0.000 description 2
- JNCMHMUGTWEVOZ-UHFFFAOYSA-N F[CH]F Chemical compound F[CH]F JNCMHMUGTWEVOZ-UHFFFAOYSA-N 0.000 description 2
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 2
- 108010081348 HRT1 protein Hairy Proteins 0.000 description 2
- 102100021881 Hairy/enhancer-of-split related with YRPW motif protein 1 Human genes 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical compound [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 2
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- BTANRVKWQNVYAZ-UHFFFAOYSA-N butan-2-ol Chemical compound CCC(C)O BTANRVKWQNVYAZ-UHFFFAOYSA-N 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 239000007795 chemical reaction product Substances 0.000 description 2
- 238000005660 chlorination reaction Methods 0.000 description 2
- 150000001879 copper Chemical class 0.000 description 2
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical compound Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 description 2
- 238000005695 dehalogenation reaction Methods 0.000 description 2
- 230000001419 dependent effect Effects 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 238000003682 fluorination reaction Methods 0.000 description 2
- 229910052731 fluorine Inorganic materials 0.000 description 2
- 239000011737 fluorine Substances 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 239000000543 intermediate Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Natural products C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000011946 reduction process Methods 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- OCKGFTQIICXDQW-ZEQRLZLVSA-N 5-[(1r)-1-hydroxy-2-[4-[(2r)-2-hydroxy-2-(4-methyl-1-oxo-3h-2-benzofuran-5-yl)ethyl]piperazin-1-yl]ethyl]-4-methyl-3h-2-benzofuran-1-one Chemical compound C1=C2C(=O)OCC2=C(C)C([C@@H](O)CN2CCN(CC2)C[C@H](O)C2=CC=C3C(=O)OCC3=C2C)=C1 OCKGFTQIICXDQW-ZEQRLZLVSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 241000331231 Amorphocerini gen. n. 1 DAD-2008 Species 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- XPDWGBQVDMORPB-UHFFFAOYSA-N Fluoroform Chemical compound FC(F)F XPDWGBQVDMORPB-UHFFFAOYSA-N 0.000 description 1
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 1
- ZOKXTWBITQBERF-UHFFFAOYSA-N Molybdenum Chemical compound [Mo] ZOKXTWBITQBERF-UHFFFAOYSA-N 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- BQCADISMDOOEFD-UHFFFAOYSA-N Silver Chemical class [Ag] BQCADISMDOOEFD-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical class [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 229910052783 alkali metal Inorganic materials 0.000 description 1
- 229910000272 alkali metal oxide Inorganic materials 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 239000000956 alloy Substances 0.000 description 1
- 229910045601 alloy Inorganic materials 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- 229910052787 antimony Inorganic materials 0.000 description 1
- WATWJIUSRGPENY-UHFFFAOYSA-N antimony atom Chemical compound [Sb] WATWJIUSRGPENY-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 239000010941 cobalt Chemical class 0.000 description 1
- 229910017052 cobalt Inorganic materials 0.000 description 1
- GUTLYIVDDKVIGB-UHFFFAOYSA-N cobalt atom Chemical class [Co] GUTLYIVDDKVIGB-UHFFFAOYSA-N 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 238000006298 dechlorination reaction Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- IOCGMLSHRBHNCM-UHFFFAOYSA-N difluoromethoxy(difluoro)methane Chemical compound FC(F)OC(F)F IOCGMLSHRBHNCM-UHFFFAOYSA-N 0.000 description 1
- WEHWNAOGRSTTBQ-UHFFFAOYSA-N dipropylamine Chemical compound CCCNCCC WEHWNAOGRSTTBQ-UHFFFAOYSA-N 0.000 description 1
- 230000004992 fission Effects 0.000 description 1
- 229940084362 forane Drugs 0.000 description 1
- 235000019256 formaldehyde Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 150000004820 halides Chemical group 0.000 description 1
- 230000026030 halogenation Effects 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 235000010299 hexamethylene tetramine Nutrition 0.000 description 1
- VKYKSIONXSXAKP-UHFFFAOYSA-N hexamethylene tetramine Natural products C1N(C2)CN3CN1CN2C3 VKYKSIONXSXAKP-UHFFFAOYSA-N 0.000 description 1
- 239000004312 hexamethylene tetramine Substances 0.000 description 1
- 238000010505 homolytic fission reaction Methods 0.000 description 1
- 150000004678 hydrides Chemical class 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 125000002346 iodo group Chemical group I* 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- WPBNNNQJVZRUHP-UHFFFAOYSA-L manganese(2+);methyl n-[[2-(methoxycarbonylcarbamothioylamino)phenyl]carbamothioyl]carbamate;n-[2-(sulfidocarbothioylamino)ethyl]carbamodithioate Chemical class [Mn+2].[S-]C(=S)NCCNC([S-])=S.COC(=O)NC(=S)NC1=CC=CC=C1NC(=S)NC(=O)OC WPBNNNQJVZRUHP-UHFFFAOYSA-L 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 229910052750 molybdenum Inorganic materials 0.000 description 1
- 239000011733 molybdenum Substances 0.000 description 1
- HVOYZOQVDYHUPF-UHFFFAOYSA-N n,n',n'-trimethylethane-1,2-diamine Chemical compound CNCCN(C)C HVOYZOQVDYHUPF-UHFFFAOYSA-N 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- WIKCEBWXWSHGTB-UHFFFAOYSA-N octane;pyridine Chemical compound C1=CC=NC=C1.CCCCCCCC WIKCEBWXWSHGTB-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 125000000075 primary alcohol group Chemical group 0.000 description 1
- XOJVVFBFDXDTEG-UHFFFAOYSA-N pristane Chemical compound CC(C)CCCC(C)CCCC(C)CCCC(C)C XOJVVFBFDXDTEG-UHFFFAOYSA-N 0.000 description 1
- 238000011027 product recovery Methods 0.000 description 1
- 230000036647 reaction Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 150000003333 secondary alcohols Chemical class 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- 229910052709 silver Inorganic materials 0.000 description 1
- 239000004332 silver Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000011135 tin Chemical class 0.000 description 1
- 229910052718 tin Inorganic materials 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 229960001124 trientine Drugs 0.000 description 1
- 229910052720 vanadium Inorganic materials 0.000 description 1
- GPPXJZIENCGNKB-UHFFFAOYSA-N vanadium Chemical compound [V]#[V] GPPXJZIENCGNKB-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C41/00—Preparation of ethers; Preparation of compounds having groups, groups or groups
- C07C41/01—Preparation of ethers
- C07C41/18—Preparation of ethers by reactions not forming ether-oxygen bonds
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Process for replacing a halogen substituent with hydrogen in a halogenated aliphatic ether of methyl-methyl type or ethyl-ethyl type comprising reacting the ether with a primary or secondary alkanol and an inorganic base. The process is particularly useful for the production of certain inhalent anaesthetics.
Description
SPECIFICATION
Process for adjusting the halogen content of halogenated aliphatic ethers
This invention relates to processes for adjusting the halogen content of halogenated aliphatic ethers, by selective reduction, ie, replacement of a halide substituent on the ether with a hydrogen. More specifically, the invention is concerned with new processes, and with improvements in existing processes, for the production of certain halogenated aliphatic ethers that are useful as inhalant anaesthetics.
The halogenated ether 1,1,2-trifluoro-2 chloroethyl difluoromethyl ether, CHF20CF2CHFCI, is a valuable inhalant anaesthetic, enflurane, made and sold underthe trademark ETHRANE by Airco Inc,
Montvale, New Jersey 07645. It is referred to hereafter as enflurane.
The presently-employed process for manufacturing this anaesthetic material generates a number of by-product streams, each characterised by having more chlorine in the molecule than does the desired anaesthetic product One such by-product stream contains the compound of CF2HOCF2CFCI2, which is very difficult to remove from the desired product by distillation or other separating technique, and of course, it represents a yield loss for the presentlyemployed process.
Other by-product streams are produced in the presently-employed process as "bottoms" from the vacuum stills. These bottoms contain the following components in varying proportions:
CH2CIOCF2CHFCI CCl3OCF2CHFCl CCI2HOCF2CHFCI CCl2HOCF2CFCl2
CClH2OCF2CFCl2
CCl3OCF2CFCl2 At the present time, these materials are useless by-products that reduce the efficiency of the currently-employed process.
Another important halogenated ether anaesthetic is 1-chloro-2-trifluoro difluoromethyl ether, CF3CHCIOCHF2, isoflurane, made and sold under the trademark FORANE by Airco Inc. It is referred to hereafter as isoflurane. In the process for manufacturing this anaesthetic, care must be exercised to avoid by-product formation, and the process now in use achieves low conversions to the desired product.
Representative by-products produced include CF3CCI2OCHF2, which has been considered to be useless in the past.
The selective reduction of halogenated aliphatic ethers is extremely difficult to accomplish because of the different responses exhibited by ethers of this kind to a given reactant or to given reactants. Thus, there are three important reactions that halogenated aliphatic ethers may undergo in the presence of a base.
First, a hydrolysis or nucleophilic displacement reaction may occur. This is a reaction in which the halogen atom is replaced by OH, OR, or other nuc leophilicgroup, as represented by the equation:
B + R-O-R'CI-- > RO-R'-B + Cl where B is OH or OR.
Second, dehydrohalogenation may occur. In this reaction, hydrogen and halogen are removed from adjacent carbon atoms to form a double bond:
This type of reaction is described in US patent 2 803 666 where this reaction occurs: 40"C (CCI3CHCI)2 O + C2H5OH + KOH -- > CCI2 = CCIOCCI = 0012.
It is also described by Corley et al in 78 JACS 3489 at 3491 and 3492, as for example in this preparation:
reflux
22 hrs
Third, selective reduction may take place, in accordance with the present invention. In this reaction the halogen is replaced by hydrogen, as in the examples of this application.
In order for the reduction reaction to work, the ether must not undergo a hydrolysis or nucleophilic displacement reaction or dehydrohalogenation reaction, which is faster than the reduction. In addition, any ether formed by the reduction reaction must not undergo further reactions, especially dehydrohalogenation.
In order for selective reduction to take place, rather than hydrolysis or nucleophilic displacement or rehydrohalogenation, certain conditions must be met. The reactions of the halogenated ethers have been little explored and have been considered highly unpredictable. The present invention is remarkable in that only certain halogenated ethers can be selectively reduced, and in that the reduction is selective.
It has now been discovered that selective replacement of a chlorine or bromine substituent on certain halogenated aliphatic ethers, with hydrogen, can be accomplished by reacting one of the certain substituted ethers with alkanol and a base, preferably but not necessarily in the presence of a catalyst.
The halogen replaced may be bonded to a terminal carbon orto an inner carbon.
The process of the invention can be concisely described as a process for replacing a halogen substituent with hydrogen in a halogenated aliphatic ether of the methyl-ethyl or ethyl-ethyl type, comprising reacting with a primary or secondary alkanol and an inorganic base a halogenated aliphatic ether of the formula: (a) CX3OCY2 OZa where
CX3 is CF3, CH3, CH2F, CF2CL, CF2Br, or CHF2;
and
CZ3CY2 is CF3CCL2, CF3CCIBr, CF3CBr2, CFCl2CF2, CFCI2CFCI, CFCI2CFBr, CFBrCICF2,
CFCIBrCFCI, CFBrCICFBr, CCl3CF2, CFBr2CF2, CFBr2CFCI, CFBr2CFBr, CCI2BrCF2, CCIBr2CF2 or CBr3CF2 or (b) CX3CY2OCY2CX3 where at least one of the CX3CY2 groups is
selected from the following:: CF3CCl2, CF3CCIBr, CF3CBr2,
CFCI2CF2, CFCl2CFCl, CFCI2CFBr,
CFBrCICF2, CFBrCICFCI, CFBrCICFBr, CCI3CF2, CFBr2CF2, CFBr2CFCI, CFBr2CFB r, CCI2BrCF2, CCIBr2CF2 or CBr3cF2; and the other CX3CY2 group may be the same or
may be selected from the following:
CF3CH2, CF3CHF, CF3CHCI, CF3CHBr,
CF3CF2, CF3CFCI, CF3CFBr, CH3CH2,
CHFCH2, CHF2CF2, CFCICF2,
CF2CICFCI, CF2CICFBr, CF2BrCF2
CHCIBrCF2 or CHBr2CF2.
In Fluorine Chemistry Reviews, by Metille and Burton, p 354, the authors describe the dehalogenation of CF3l to CF3H, using KOH in a solvent of high dielectric constant, specifically referring to ethanol. The use of the reaction to dehalogenate CF3CF21 to
CF3CF2H is also discussed.
The source article referred to by Metille and Burton is Banus et al, J. Chem. Soc. 1951, pp 60-64. This
publication states that it is known that the C-I bond in CF31 can undergo homolyticfission but that, apart from decomposition, CF3CI, CF2CI2 and CHF2CI "do not show reactions involving the homolytic or heterolytic fission of the carbon-chlorine bond." The publication in general stresses that the iodo compounds are unique as compared to the corresponding bromo or chloro compounds. It would not, therefore, suggest the use of the same type of reaction even for brominated, chlorinated, or fluorinated alkanes, let alone ethers.
Young, US patent 3391 204 in his Example 11, describes the reaction:
where TEA represents triethanolamine.
Examples 12 and 13 describe generally similar dehalogenations. Young says that alcohol may be present, but characterises the alcohol as an "inert" solvent, and his reaction did not operate on ethers, but rather on halogenated alkanes.
In German patent2 554844, partial dechlorination of F2CHOCFCICF2CI, an ether, was accomplished by the use of hydrogen and a catalyst of either palladium or a complex metallic hydride.
Some reactions involving halogenated alkanes are to be found in the literature. US patents 3 527 813 and 3 535388 describe the introduction of chlorine and of fluorine into halogenated alkanes.
The present invention involves the discovery that when a halogenated aliphatic ether initial compound, selected from a limited class of halogenated ethers as defined above, is reacted with an alkanol and a base, one chlorine or one bromine is selectively replaced with hydrogen. This is a rather remarkable reaction because it occurs despite the presence on the same molecule of
F F
-CF3 or - C - or F- C - groups, where X is chlorine
X X or bromine. It is also a very valuable reaction because it is specific and permits the conversion of previously useless by-products to valuable products, and also offers a newtool for synthesis.
The two primary areas of immediate commercial interest relate to the preparation of the two inhalant anaesthetics mentioned above, as follows.
Preparation of Enflurane Anaesthetic, CHF2OCF2CHFCl The halogenated ether CF2HOCF2CFCI2 is a particularly undesirable by-product of the presentlyemployed process for the preparation of enflurane anaesthetic. It is readily reduced to enflurane in good yield by the process of the present invention, as follows:
(enflurane anaesthetic)
Using this reaction, a product stream from the presently employed process for producing enflurane that contains this by-product I, can be upgraded by reacting the product stream itself to convert the by-product I to enflurane,in situ. The enflurane itself, that is present in the product stream, is not affected by the reaction.
In addition, the other halogenated ether byproducts mentioned above, that are produced as "bottoms", can be further processed by distillation and chlorination to obtain a mixture containing a high proportion oftheetherCHCl2OCF2CFCl2. Fluorination of this ether leads to I above, which can then be reacted in accordance with the invention to produce more enflurane, thus materially improving overall process yield and economics.
It should be noted that when the alkanol employed is methanol, 1.5 moles are required per mole of ether, so that the equations above and below, that employ methanol, are not balanced. The reason is that methanol undergoes the Cannizzaro reaction.
When other suitable alkanols are employed which do not give a Cannizzaro reaction, the reaction requires one mole of the alkanol to one mole of reactant ether.
Preparation oflsoflurane Anaesthetic CF3CHClO CHF2 In the isoflurane manufacturing process, CF3CH2OCHF2 is chlorinated to give CF3CHCIOCHF2, isoflurane. However, the chlorination must be done at low conversions in order to avoid formation of large amounts of the by-product CF3CCl2OCHF2. However, this by-product can now be reduced to isoflurane as follows: CF3CCl2OOHF2 + NaOH + CH3OH --- > CF3
CHCIOCHF2 + NaCI + CH2O Only a limited number of halogenated ethers are susceptible to selective reduction in accordance with the invention.
As to those of the formula CX3OCY2CZ3, as defined above, those ethers that are suitable for use in the present invention were selected from a very large number of halogenated ethers of the methyl-ethyl type, based upon several rules. These results eliminate those halogenated methyl-ethyl type ethers that would not be suitable by reason of side reactions, ether initially or after reduction. These rules are:
1. No OCY2CZ3 group can havethe configuration
O-CH-CX' where X' is Br or CI, since these
compounds would probably eliminate HX' to
give -O-C=C in the presence of base.
(OF3OCHFCF2Br and CF30CHFCF2CI may be
exceptions to this rule, but are not within the
scope ofthe invention).
2. No OCY2CZ3 group shall have more than one
hydrogen on the carbon unless CY2 is CH2 or
CF2; ie. where two of the Z = H, then CY2 must
be CH2 or OF2. Otherwise the halogenated
ether compounds would not only be unstable
to base but some of them would decompose
spontaneously.
3. Within the OCY2CZ3 group, there must be
either two chlorines, two bromines, or one
bromine and one chlorine on one of the car
bon atoms, otherwise the compound will not
be reduced.
The first two rules eliminate those halogenated ethers that are unstable in the reaction mixture of this invention. The third rule confines those ethers that have survived the screening by rules 1 and 2 to those that would be reduced, and in addition, eliminates reduced compounds that would not be stable in the presence of the base in the reaction mixture.
The application of these rules, of course, severely limits the number of halogenated ethers that are available for use in the selective reduction process of the invention.
The same considerations can be applied in identifying those halogenated ethers of the ethyl-ethyl type that are suitable for use in practising the invention.
The alkanol reactant is a primary or secondary alcohol, preferably a 1 to 4 carbon alkanol (ie. a lower alkanol), but alkanols of any known chain length up to about 12 carbons are useful and can be expected to be effective, although even higher alcohols are operative. Water soluble alcohols are preferred. The alkanol may be substituted but preferably is not, as a matter of economics. While methanol and ethanol are generally preferred because of availability and cost, isopropanol and sec-butanol are useful and also are readily available.
The base may be: an alkali metal dissolved in the alkanol; an alkali metal or alkaline earth metal hyd
roxide, dry or in aqueous or alcoholic solution; or any strongly basic material that does not interfere with the desired reaction. Sodium hydroxide, sodium methylate, potassium hydroxide, lithium hydroxide and calcium hydroxide, are examples of suitable basic materials. Ammonia and sodium carbonate are useful in many reactions.
Catalysts are generally not essential but are useful for many individual reactions in improving reactions rates, yields or both. The catalyst, in finely divided or other suitable state, may be a metal-containing (advantageously, in most cases, a varivalent metalcontaining) catalyst, more particulariy, a coppercontaining catalyst such as metallic (elementary) copper or a copper salt of an inorganic or organic acid, eg. copper chloride, bromide, nitrate, acetate, propionate, etc; or corresponding salts of silver, cobalt, tin, manganese, nickel, iron, molybdenum, chromium, antimony, vanadium and the like, or the said varivalent metals in elementary form, or alloys thereof with each other or with other metals. Preferably, a copper-containing catalyst, specifically elementary copper in powder form, or a copper salt, is employed.In general, the use of a catalyst comprising, for example, one or more of the metals identified above, or the inorganic or organic salts thereof, tends to produce higher conversions, shorter induction periods, and lower operating temperatures.
Preferred catalysts include not only the finely divided metals, metal salts, but also the amines, and mixtures thereof with metal powders and metal salts. The most preferred catalysts are mixtures of copper chloride with triethanolamine. Other suitable amines that may be used, depending on the particular reaction, include::
Methylamine (monomethylamine) Hexamethylenetetramine
Dimethylamine Ammonium chloride
Diethylamine Benzyl trimethyl ammonium methoxide
Triethylamine Ethylene diamine
Isopropylamine Triethylene tetramine
Di-n-propylamine N,N,N-trimethyl ethylene diamine
Piperidine N,N-diethylene diamine
Morpholine 1,2-cyclohexylene dinitrilo acetic
Monoethanolamine acid
Diethanolamine 3-dimethylamino propylamine
Hydrazine Ethylenediamine tetraacetic acid
Aniline Diazo bicyclo (2,2,2,) octane
Pyridine N-(2-amino ethyl morpholine)
Conditions ofReaction
The alkanol and base should be employed in
excess over the theoretical amount required to effect
the desired reduction of the ether. The alkanol may
function both as a reactant and solvent and may be
present in substantial excess for that reason.The
limits are those established by the practical consid
erations of reaction kinetics, ease of recovery of the
product, and conservation of energy.
The temperature of the reaction is dependent upon the particular reactants employed and may range, for example, from about 0 C to about 100 -120 C or higher and, preferably, from about 200otto 8000. The temperature and/or pressure advantageously are such that the reaction mass is in a liquid state during the course of the reaction. The reaction is exothermic, and once initiated, may require cooling, depending upon the equipment available and other conditions.
The time of the reaction is not important since one
may prefer to carry out the reaction for a relatively
short period of time with a relatively low conversion
rate, ratherthanto make the reaction go substan
tially to completion. In general, the time of the reac
tion depends upon the particular reactants emp
loyed, the temperature of the reaction, the efficacy of the catalyst or catalyst system (if employed) and other influencing factors. Generally, just a few hours up to about thirty, is adequate to produce a suitable yield.
The pressure used is dependent primarily upon the particular reactants employed. The reaction may be carried out at atmospheric pressure. The pressure employed seems to have no material effect on the course of the reaction.
The product may be isolated by any suitable means from the reaction mass. Ordinarily, the product is insoluble and is precipitated by a water-wash, which removes any water-soluble reaction products and by-products.
To explain the invention further, several demonstrations of it are reported in the following examples.
Aii temperatures are in "C, and all parts and percentages by weight, as is, unless expressly stated to be otherwise.
Example 1
Production oflsofluraneAnaesthetic
(isoflurane
anaesthetic)
A mixture of CF3CCI20CHCI2 (44 g, 0.2 mole), 50%
aqueous sodium hydroxide solution (20 g. 0.25 mole), methanol (100 ml) Cud2 (1 g), and triethanolamine (1 g), was refluxed for five hours and poured into water. The water-insoluble layer was analysed by gas chromatography and found to contain 16% unreacted CF3CCI2OCHF2, 25% methanol, and 54% CF3CHCIOCHF2 (isoflurane anaesthetic).
Example 2 Different Reactant Ether, with Cata/ysts
Example 2A
Production of Enflurane CHF2OCF2CFCI2 (Material 2) + NaOH + CH3OH --- >
TEA
CHF2OCF2CHFCI (enflurane anaesthetic)
A mixture of CH2OCF2CHCI2 (44 g, 0.2 mole), 50%
aqueous sodium hydroxide (20 g, 0.25 mole)
methanol (100 ml), CuCI2 (1 g), and triethanolamine
(1 g), was refluxed for seven hours and then poured
into water. The water-insoluble product recovered
(34 g) was analysed by gas chromatography and found to be 77% unreacted CHF2OCF2CFCI2 (Material 2) and 18% CHF2OCF2CHFCI (enflurane).
Material 2 can be separated as a "bottom" in a still from the enflurane product, for recyling through the process. The enflurane distillate, in purified form, is useful as an inhalant anaesthetic.
Example 2B
Purification of Enflurane
A reaction product containing enfiurane together
with about 5% of Material 2 was purified as follows.
A mixture of CHF2OCF2CHFCI (95.6 g) and CHF2OCF2CFCI2 (4.4 g), methanol (15 ml), copper (1 g), ethanolamine (6 g), and sodium hydroxide pellets (8 g), was refluxed for five hours and then washed with water. The water insoluble product (88.9 g) was shown by gas chromatography to be 99.7% pure
CHF2OCF2CHFCI, with no CHF2OCF2CF512 present.
Example 2C Enfiurane Preparation with a Catalyst System A mixture Gf CHF20CF2CFCl2 (22 g, 0.1 mole), methanol (50 ml), 50% aqueous sodium hydroxide solution (24 g, 0.3 mole), ethanolamine (6 g), and copper metal (1 g), was refluxed for 24 hours. The reaction mixture was washed with water to give 10.9 g of water insoluble product, which was analysed by gas chromatrography and shown to be 90%
CHF2OCF2CHFCI. There was no unchanged starting material present.
When this procedure was repeated, but with the use of 75 ml. of methanol ratherthan 50 ml, the water insoluble product recovered amount to 10.6 g, which is considered to be an insinnificant difference.
Example 3
Different Reactant Ether
Example 3A
Small Scale Preparation
(Product 3)
A mixture of CF2CIOCF2CFCI2 (25.3 g, 0.1 mole), methanol (50 ml) 50% aqueous sodium hydroxide solution (16 g, 0.2 mole), triethanolamine (1 g), and
CuCI2 (1 g), was refluxed for nineteen hours. The reaction mixture was poured into water and 19 g of water-insoluble product recovered. This was analysed by gas chromatography and shown to be about 91% CF2CIOCF2CHFCI (Product 3).
Product 3 is useful as a solvent and degreasing agent.
Example 3B
Larger Scale Preparation
This reaction was repeated on a larger scale, and with a more detailed characterisation of the product, as follows:
A mixture of CF2CIOCF2CFCI2 (253 g, 1 mole), methanol (750 ml), 50% aqueous sodium hydroxide (120 g, 1.5 mole), CuCI2 (10 g), andtriethanolzmine (10 g), was refluxed for 24 hours.
At the end of this time, 85% of the sodium hydroxide had reacted as shown by titration. The reaction mixture was distilled to recover 280 g of the product, b.p. 53 -64 , which was washed with water to give 204 g. containing 69% CF2CIOCF2CHFCI (Product 3) and 27% unreacted CF2CIOCF2CFCI2. This was redistilled to recover in purified form CF2CIO ::F2CHFCI (Product3), b.p. 64 , which was identified by its NMR spectrum.
Example 4 DifFerentReactantEther
(Product 4)
A mixture of CF3CCI2OCF2CI (50 g, 0.2 mole), methanol (100 ml) 50 /O aqueous sodium hydroxide solution (48 g, 0.6 mole), CuOl2 (2 g), and triethanolamine (2 g), was refluxed for five hours.
The reaction mixture was washed with water to give 34 g. of water-insoluble product material which was analysed by gas chromatography and shown to be 79% CF3CHCiOCF2Ci (Product 4), which is useful as a solvent and degreasing agent.
In a different run, a reaction mixture of the same composition, after refluxing for 68 hours, produced a major amount of Product 4.
In still another run, a reaction mixture ofthe same composition except for the sodium hydroxide, which was present in an amount of 24 g. (0.3 mole), produced after4 hours of reflux, a product containing over 90% of Product 4.
Example 5
Four Carbon Reactant Ether
(Product 5)
A mixture of CF3CCI2OCHCICF3 (15 g, 0.053 mole), 50% aqueous sodium hydroxide solution (6.4 g, 0.08 mole), methanol (59 ml), CuCI2 (0.1 g), and triethanolamine (0.1 g), was refluxed for four hours and poured into water. The water-insoluble product (10 g) was analysed by vapour phase chromatography and found to contain 48% CF3CHCIOCHCICF3 (Product 5), (dl form), 38% CF3CHCIOCHCiCF3 (meso form), and 8% unreacted starting material.
Product 5 is useful as a solvent and degreasing agent.
Example 6 Criticality of Ether Reactant
A mixture of CF3CHCIOCF2CI (5.4 g, 0.025 mole), methanol (10 ml), 50% aqueous sodium hydroxide (4 g, 0.05 mole), CuOl2 (0.25 g), and TEA (0.25 g) was refluxed overnight. The water-insoluble product (2 g) was subjected to NMR spectroscopy. The spectrum showed multipet centered (6 peaks) around 5.8 and two OH3O singlets. None of the expected triplet for -OCHF2 was present. It is concluded that this starting ether does not undergo selective reduction in accordance with the invention.
The invention provides á valuable, speclfictechni- que for selectively modifying the halogenation of a halogenated aliphatic ether, by a selective reduction process that substitutes a hydrogen substitute for a particular halogen substituent. The process thus makes possible the conversion of hitherto useless halogenated aliphatic ethers to materials that are either usefulperse or that can be converted by further processing to directly useful materials.
The invention is of particular value in connection with the production of enflurane anaesthetic, since it not only permits the conversion of a major byproduct, CHF2OCF2CFCI2, into the desired enflurane anaesthetic product, as in Example 2, which is an important advance in the art in and of itself, but it also eliminates the need that previously existed for separating this material from the product stream containing the enflurane (a difficult task because of the many physical and chemical similarities between the compounds and the closeness of their boiling points).
Thus, in the conversion of by-products from the manufacture of enflurane, the "bottoms" are chlorinated to obtain a mixture containing a high propor tion of the compound CHCI2OCF2CFCI2. Fluorination of this compound produces CF2HOCF2CFCI2, which can be reduced by the process of the invention to enflurane, as in Example 2.
The process of this invention has the advantage of being highly specific, in the sense that few unwasted materials appear in the reaction mixture produced.
Product recoveries and purifications are thus facilitated and made less expensive. The many useless by-products produced by the presently-employed process are either avoided completely because of the new synthesis tool that is available, or the quantity and number is reduced.
The process provides new ways to synthesise valuable materials and, in addition, provides a way to convert presently useless or unusual halogenated by-products into valuable intermediates.
BY$PRODUCTS INTO VALUABLE INTERMEDIATES.
Claims (9)
1. A process for replacing a halogen substituent with hydrogen in a halogenated aliphatic ether of the methyl-ethyl or ethyl-ethyl type, comprising reacting with a primary or secondary alkanol and an inorganic base a halogenated aliphatic ether of the formula:
(a) CX3OCY2CZ3 where
CX3 is OF3, CH3, CH2F, CF2CI, CF2Br, or CHEF2; and
CZ3CY2 is CF3CCI2, CF3CCIBr, CF3CBr2, CFC12CF2, CMCI2CFCI, CFCI2CFBr, CFBrCICF2, CFCIBrCFCI,
CFBrCICFBr, CCI3CF2, CFBr2CF2, CFBr2CFCI,
CFBr2CFBr, CCl2BrOF2, CCIBr2CF2 or CBr3CF2
or
(b) CX3CY2OCY2CX3 where at least one of the CX3CY2 groups is selected from the following::
CF3CCI2, CF3CCIBr, CF3CBr2, CFCl2CF2, CFCI2CFCI, CFCI2CFBr, CFBrCICF2, CFBrCICFCI,
CFBrCICFBr, CCI3CF2, CFBr2CF2, CFBr2CFCI,
CFBr2CFBr, CCI2BrCF2, CCIBr2CF2 or CBr3CF2; and the other CX3CY2 group may be the same or may be selected from the following:
CF3CH2, CF3CHF, CF3CHCI, CF3CHBr, CF3CF2,
CF3CFCI, CF3CFBr, CH3CH2, CHFCH2, CHF2CF2,
CFCICF2, CF2CICFClx CF2CICFBr, CF2CF2x CF2BrCFCI, CF2BrCFB r, CHFBrCF2, CHC12CF2, CHCIBrCF2 or CHBr2CF2.
2. A process as claimed in claim 1 wherein the aliphatic ether reactant is: CF3CCI20CHF2 and the reduced ether product is:
CF3CHCIOCHF2
3. A process as claimed in claim 1 wherein the aliphatic ether reactant is: CFCI2CF20CHF2 and the reduced ether product is: CHFCICF20CHF2
4. A process as claimed in claim 1 wherein the
aliphatic ether reactant is: CFCI2CF20CF2CI and the reduced ether product is: CHFCICF20CF2CI.
5. A process as claimed in claim 1 wherein the
aliphatic ether reactant is: CF3CCI20CF2CI and the reduced ether product is:
CF3CHCIOCF2CI
6. A process as claimed in claim 1 wherein the aliphatic ether reactant is: CF3CCI20CHCICF3 and the reduced ether product is:
CF3CHCIOCHCICF3
7. A process as claimed in any one of claims 1 to 6, wherein the reaction is conducted in the presence of a catalyst selected from the group consisting of a varivalent metal powder, the salt of a varivalent metal, an amine, and mixtures of any two or more thereof.
8. A process as claimed in any one of claims 1 to 7, wherein the alkanol is a lower alkanol.
9. A process for replacing a halogen substituent with hydrogen in a halogenated aliphatic ether sub stantial ly as hereinbefore described.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1995379A | 1979-03-12 | 1979-03-12 |
Publications (2)
Publication Number | Publication Date |
---|---|
GB2044263A true GB2044263A (en) | 1980-10-15 |
GB2044263B GB2044263B (en) | 1983-08-03 |
Family
ID=21795966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GB8006975A Expired GB2044263B (en) | 1979-03-12 | 1980-02-29 | Reduction of halogenated ethers |
Country Status (5)
Country | Link |
---|---|
CA (1) | CA1129892A (en) |
DE (1) | DE3008027C2 (en) |
FR (1) | FR2451358A1 (en) |
GB (1) | GB2044263B (en) |
IT (1) | IT1141220B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613876A1 (en) * | 1991-09-30 | 1994-09-07 | Ohmeda Pharmaceutical Products Division Inc. | Preparation of isoflurane |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1503999A (en) * | 1975-12-05 | 1978-03-15 | Ici Ltd | Preparation of halogenated methyl ethyl ethers |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3689459A (en) * | 1970-08-10 | 1972-09-05 | Baxter Laboratories Inc | Novel ether |
-
1980
- 1980-01-29 CA CA344,581A patent/CA1129892A/en not_active Expired
- 1980-02-18 IT IT19982/80A patent/IT1141220B/en active
- 1980-02-29 GB GB8006975A patent/GB2044263B/en not_active Expired
- 1980-03-03 DE DE3008027A patent/DE3008027C2/en not_active Expired
- 1980-03-10 FR FR8005346A patent/FR2451358A1/en active Granted
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB1503999A (en) * | 1975-12-05 | 1978-03-15 | Ici Ltd | Preparation of halogenated methyl ethyl ethers |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0613876A1 (en) * | 1991-09-30 | 1994-09-07 | Ohmeda Pharmaceutical Products Division Inc. | Preparation of isoflurane |
JP3325295B2 (en) | 1991-09-30 | 2002-09-17 | バクスター・インターナショナル・インコーポレイテッド | Method for producing isoflurane |
Also Published As
Publication number | Publication date |
---|---|
CA1129892A (en) | 1982-08-17 |
GB2044263B (en) | 1983-08-03 |
DE3008027A1 (en) | 1980-09-18 |
FR2451358B1 (en) | 1985-03-22 |
IT1141220B (en) | 1986-10-01 |
IT8019982A0 (en) | 1980-02-18 |
FR2451358A1 (en) | 1980-10-10 |
DE3008027C2 (en) | 1982-07-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20080300432A1 (en) | Chemical Production Processes and Systems | |
JPS6197234A (en) | Manufacture of haloaromatic compound | |
US4096185A (en) | Preparation of p-aminobenzotrifluoride | |
US5723684A (en) | Compositions for bis-(fluoromethyl)ether | |
CA1293739C (en) | Process for preparing 2,2,3-trifluoropropionyl fluoride | |
US4346246A (en) | Process for adjusting the halogen content of halogenated aliphatic ethers | |
US6476281B2 (en) | Method for the preparation of 1,1,1,3,3-pentafluoropropene and 1,1,1,3,3-pentafluoropropane | |
GB2044263A (en) | Reduction of halogenated ethers | |
KR100394877B1 (en) | New intermediates for the synthesis of trifluoromethylated organic compounds | |
US4365097A (en) | Process for the preparation of halogenated aliphatic ethers | |
JPS59134754A (en) | Preparation of bis(2-(n,n-dimethylamino)ethyl)ether | |
JP2983355B2 (en) | Method for dechlorination and / or debromination of fluorine- and chlorine- and / or bromine-containing aromatic compounds | |
EP0097357B1 (en) | Process for preparing trifluoromethylbenzene derivatives | |
US5283378A (en) | Process for the dechlorination and/or debromination of fluorine-and chlorine- and/or bromine-containing aromatic compounds | |
JPS63201144A (en) | Manufacture of trialkoxybenzaldehyde | |
JPWO2019189716A1 (en) | Method for producing fluorine-containing sulfide compound | |
EP0155093B1 (en) | Method for production of fluorine-containing aromatic derivative | |
JPS6335548A (en) | Production of triarylamine | |
JP4258695B2 (en) | O- (perfluoroalkyl) dibenzofuranium salt derivative, production intermediate thereof, production method of the production intermediate, perfluoroalkylating agent, and perfluoroalkylation method | |
JPS62501504A (en) | Copper-diamine complex and method for producing diamine | |
JPS6259247A (en) | Production of aminophenyl ether compound | |
JPS6350339B2 (en) | ||
JPH04234825A (en) | Process for producing benzotrifluoride compound | |
JP3149537B2 (en) | Method for producing 1H-perfluoroalkane | |
KR100664667B1 (en) | Fluorinated benzene manufacturing process |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
732 | Registration of transactions, instruments or events in the register (sect. 32/1977) | ||
PCNP | Patent ceased through non-payment of renewal fee |